Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy INmune Bio stock | $10.22

Own INmune Bio stock in just a few minutes.

Fact checked

INmune Bio, Inc is a biotechnology business based in the US. INmune Bio shares (INMB) are listed on the NASDAQ and all prices are listed in US Dollars. INmune Bio employs 4 staff and has a market cap (total outstanding shares value) of USD$171.5 million.

How to buy shares in INmune Bio

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for INmune Bio. Find the stock by name or ticker symbol: INMB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until INmune Bio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$10.22, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of INmune Bio, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of INmune Bio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

INmune Bio share price

Use our graph to track the performance of INMB stocks over time.

INmune Bio shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$10.22
52-week rangeUSD$2.2 - USD$16.25
50-day moving average USD$9.175
200-day moving average USD$9.1897
Wall St. target priceUSD$20
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.618

Buy INmune Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy INmune Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

INmune Bio price performance over time

Historical closes compared with the close of $10.22 from 2020-12-18

1 week (2021-01-14) -58.99%
1 month (2020-12-24) -19.84%
3 months (2020-10-22) 21.38%
6 months (2020-07-22) -19.97%
1 year (2020-01-22) 94.66%
2 years (2019-01-20) N/A
3 years (2018-01-20) N/A
5 years (2016-01-20) N/A

INmune Bio financials

Gross profit TTM USD$0
Return on assets TTM -20.8%
Return on equity TTM -34.02%
Profit margin 0%
Book value $3.064
Market capitalisation USD$171.5 million

TTM: trailing 12 months

Shorting INmune Bio shares

There are currently 487,267 INmune Bio shares held short by investors – that's known as INmune Bio's "short interest". This figure is 9.4% down from 537,918 last month.

There are a few different ways that this level of interest in shorting INmune Bio shares can be evaluated.

INmune Bio's "short interest ratio" (SIR)

INmune Bio's "short interest ratio" (SIR) is the quantity of INmune Bio shares currently shorted divided by the average quantity of INmune Bio shares traded daily (recently around 81482.775919732). INmune Bio's SIR currently stands at 5.98. In other words for every 100,000 INmune Bio shares traded daily on the market, roughly 5980 shares are currently held short.

However INmune Bio's short interest can also be evaluated against the total number of INmune Bio shares, or, against the total number of tradable INmune Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case INmune Bio's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 INmune Bio shares in existence, roughly 40 shares are currently held short) or 0.0526% of the tradable shares (for every 100,000 tradable INmune Bio shares, roughly 53 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against INmune Bio.

Find out more about how you can short INmune Bio stock.

INmune Bio share dividends

We're not expecting INmune Bio to pay a dividend over the next 12 months.

INmune Bio overview

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was founded in 2015 and is headquartered in La Jolla, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site